Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0277787 (stigma)
 13,352 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This study assessed diurnal cortisol functioning in relation to stigma-based transition-specific stressors experienced by transgender men during their transition from female to male. Sixty-five healthy transgender men undergoing testosterone therapy participated in in-person interviews through which transition-specific stressors were identified. Interviews were coded according to participant reported (1) Transitioning-identity stress; (2) Coming Out stress; (3) Gender-specific Public Bathroom stress; and (4) levels of general Perceived Stress. Participants provided fifteen salivary samples assessing cortisol diurnal rhythm over three days. Hierarchical linear models, adjusted for duration of time on testosterone therapy, body mass index, steroid-related medication use, mean awakening time, and CAR, confirmed that elevated diurnal cortisol levels at awakening were associated with transition-specific social stressors including experiencing Transitioning-identity stress, frequent Coming Out stress, and Gender-specific Public Bathroom stress. Transitioning-identity stress and Gender-specific Public Bathroom stress also predicted a steeper negative slope at awakening. General Perceived Stress was not associated with elevated cortisol or slope. These results clarify the relation of increased cortisol at awakening with a negative linear slope to perceived stigma and transition-related stress experience among transgender men.
 ...
PMID:Stigma and diurnal cortisol among transitioning transgender men. 2851 Oct 45

Acquired immune deficiency syndrome (AIDS), which is caused by HIV infection, is an epidemic disease that has killed millions of people in the last several decades. Although combination antiretroviral therapy (cART) has enabled tremendous progress in suppressing HIV replication, it fails to eliminate HIV latently infected cells, and infected individuals remain HIV positive for life. Lifelong antiretroviral therapy is required to maintain control of virus replication, which may result in significant problems, including long-term toxicity, high cost, and stigma. Therefore, novel therapeutic strategies are urgently needed to eliminate the viral reservoir in the host for HIV cure. In this review, we compare several potential strategies regarding HIV cure and focus on how we might utilize chimeric antigen receptor-modified T cells (CAR T) as a therapy to cure HIV infection.
 ...
PMID:Advances in Developing CAR T-Cell Therapy for HIV Cure. 3221 Sep 65